Reports and Surveys | October 1, 2026

GLP-1s Have Disrupted the Market for Other Diabetes Drugs

American Diabetes Association guidelines increasingly position glucagon-like peptide-1 receptor agonists (GLP-1s) earlier in treatment for many patients with type 2 diabetes. The growth in use of GLP-1s to treat diabetes has been dramatic.

Almost half of diabetics now use Mounjaro®, Ozempic® or other GLP-1s, according to a recent analysis of data from SHAPE, Segal’s proprietary health data warehouse.

Get the Infographic

GLP-1s Have Disrupted the Market for Other Diabetes Drugs Download Now

GLP-1s are so successful at treating diabetes that prescribers have been able to take patients off other medications.

Our analysis found that between January 2021 and June 2026:

  • The percentage of insulin users has been cut almost in half.
  • The percentage of users of the generic drug Metformin dropped 17 points.
  • Fewer than 2 percent of diabetics now use DPP-4 inhibitors.

Download our infographic to see the results of our analysis.

SHAPE includes information from large health plans across the United States representing a range of industries and organizations. Collectively, they cover more than four million lives.

GLP-1s impact for diabetes drug infographic cover thumbnail image

Interested in mining your own health plan data and/or benchmarking it?

Let’s have a conversation.

Get in Touch

See more insights

Female Nurse Operating MRI Scan Machine At MRI Scanner Room

What Are the Projected Health Plan Cost Trends for 2027?

Learn why some 2027 health plan cost trends are approaching 15-year highs — and how plan sponsors can manage rising costs.

Health, Multiemployer Plans, Public Sector, Healthcare Industry, Higher Education, Architecture Engineering & Construction, Pharmaceutical, Corporate

Get the Report

Woman Having Video Call With Doctor About Using A Glp 1 Medication

Behavior Change Is the Key to GLP-1 Success

GLP-1 costs can outpace short-term savings when adherence drops. Plans should align pharmacy strategy with coaching, nutrition and fitness support.

Health, Multiemployer Plans, Public Sector, Healthcare Industry, Higher Education, Architecture Engineering & Construction, Pharmaceutical, Corporate, Healthcare Cost Management

Read Full Insight

Woman Using A Glp 1 Medication

A Cost-Benefit Analysis of GLP-1s

Explore GLP 1 therapy adherence and discontinuation trends and what they mean for medical trend, pharmacy spend, rebates and total health plan costs.

Health, Multiemployer Plans, Public Sector, Healthcare Industry, Higher Education, Pharmaceutical, Corporate, Healthcare Cost Management

Get the Infographic

This page is for informational purposes only and does not constitute legal, tax or investment advice. You are encouraged to discuss the issues raised here with your legal, tax and other advisors before determining how the issues apply to your specific situations.